Business context and reporting period
The supplied filing is AmerisourceBergen Corporation’s Form 10-K for the fiscal year ended September 30, 2011—not a filing for Cencora, Inc. or a standalone fiscal fourth quarter. AmerisourceBergen operated a pharmaceutical distribution and services business, primarily in the United States and Canada, with one reportable segment.
Financial results and liquidity
Amounts are in U.S. dollars. Fiscal 2011 results compared with fiscal 2010:
| Metric | FY 2011 | FY 2010 | Change |
|---|---|---|---|
| Revenue | $80.218 billion | $77.954 billion | +2.9% |
| Gross profit | $2.539 billion | $2.357 billion | +7.7% |
| Gross margin | 3.17% | 3.02% | +15 basis points |
| Operating income | $1.203 billion | $1.104 billion | +9.0% |
| Operating margin | 1.50% | 1.42% | +8 basis points |
| Net income | $706.6 million | $636.7 million | +11.0% |
| Diluted EPS | $2.54 | $2.22 | +14.4% |
| Operating cash flow | $1.168 billion | $1.109 billion | +$59.3 million |
Fiscal fourth-quarter revenue was $20.408 billion, operating income $243.6 million, net income $147.3 million, and diluted EPS $0.54. Cash and equivalents at year-end were $1.826 billion; total debt, including current maturities, was $1.365 billion. Current assets were $11.218 billion and current liabilities $10.855 billion. Capital expenditures were $168.0 million. The company repurchased $840.6 million of shares and paid $117.6 million in dividends during the year.
Material changes versus the prior comparable period
- Revenue growth was led by 5% growth in core drug distribution (ABDC); specialty distribution and services (ABSG) revenue declined 3%, partly after a third-party logistics contract ended and dialysis sales weakened.
- Gross profit grew faster than revenue, supported by specialty and non-specialty generic programs and manufacturer service fees. The three named generic oncology products together provided about $96 million more gross-profit benefit than Oxaliplatin alone had contributed in FY 2010.
- Operating expenses rose 6.7%, including costs for the ERP transition, the Energiz program, a $16 million preliminary litigation settlement accrual, acquisition costs, and intangible impairments.
- Weighted-average diluted shares fell 3%, helping EPS grow faster than net income. Share repurchases totaled $840.6 million, compared with $470.4 million in FY 2010.
- Operating cash flow increased modestly; working capital remained significant, including a $272.3 million inventory increase, partly offset by higher payables.
Outlook, commentary, risks, and unusual items
- Management expected FY 2012 revenue to be relatively flat or grow modestly. It anticipated more than 30 brand-to-generic conversions, but expected substantially lower gross-profit contributions from Gemcitabine and Docetaxel; conversion economics were uncertain.
- The company expected about $150 million of FY 2012 capital expenditures, approximately $400 million of share repurchases subject to market conditions, and a continuing quarterly dividend. Management expected its ongoing effective tax rate to be about 38.4%.
- Major customer concentration is material: Medco represented 19% of FY 2011 revenue and about 5% of earnings. Its contract ran at least through March 2013; Medco had announced a planned merger with Express Scripts. The former Long’s Drugs customer, with about $2 billion of annual revenue, was not renewed and would no longer be serviced after September 30, 2011.
- Generic oncology product economics were moderating as competitors entered and customer reimbursement rates fell. Oxaliplatin inventory was depleted, with further quantities not expected until a planned August 2012 relaunch.
- In October 2011 the company reached a preliminary $16 million civil settlement related to qui tam allegations involving two specialty businesses; it expected final documentation in FY 2012 and did not expect those units to admit liability. Other similar allegations remained under seal and unresolved.
- Other key risks include intense price competition; generic price deflation and branded price-inflation exposure; changes to Medicare and Medicaid reimbursement and regulation; controlled-substance compliance and licensing; customer or supplier credit failure; and ERP implementation costs, delays, or control issues. The filing reports effective disclosure controls and an unqualified auditor opinion on the financial statements and internal controls.
- Subsequent events included the November 2011 acquisition of TheraCom for $250 million, a $500 million issuance of 3.5% senior notes due 2021, and extensions of credit facilities. Management expected higher FY 2012 interest expense, primarily due to the notes issuance.
Most important facts an investor should verify
- Confirm issuer identity and period: this source is AmerisourceBergen’s FY 2011 10-K, not a Cencora filing or a Q4-only report.
- Assess Medco/Express Scripts contract renewal risk and the revenue and earnings implications of losing the former Long’s Drugs business.
- Test whether expected generic launches can offset the declining contributions from existing specialty generic products and pressure on margins.
- Review the status and final cost of the qui tam settlement and other sealed claims, plus the Ontario rebate-order matter.
- Check execution and cost of the ERP transition, FY 2012 financing and debt maturities, and whether cash generation can support planned repurchases, dividends, acquisitions, and investment.